It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered ...

The stock's fall snapped a five-day winning streak.

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...